Author

Kai-Jun Wang

h-index 2 View on Semantic Scholar

We have 2 of 13 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Matching-adjusted indirect comparison of zanubrutinib and real-world chemotherapy, rituximab and chemoimmunotherapy in relapsed or refractory marginal zone lymphoma.

Aim: Traditional management of relapsed or refractory (R/R) marginal zone lymphoma (MZL) comprises chemotherapy, rituximab or rituximab-based chemoimmunotherapy (CIT). Zanubrutinib, a Bruton tyrosine kinase inhibitor, has shown high overall response rates and durable responses across MZL subtypes in two Phase II, singl...

R. Walewska, Kai-Jun Wang, C. Smare et al. · Journal of Comparative Effec... · 0 citations

Clinical trial Open access Sep 2026

First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306)

RATIONALE-306 previously demonstrated improved overall survival (OS) in participants treated with tislelizumab plus chemotherapy versus those receiving placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma, with a minimum follow-up of approximately 15 months. Explo...

H. Yoon, Ken Kato, E. Raymond et al. · Nature Communications · 0 citations